CLEC-1 Antagonist Enhances T Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack an effective method to enhance T cell responses against tumors, as inhibitory C-type lectin receptors like CLEC-1 suppress antitumor immunity by inhibiting myeloid cell activation and promoting immune evasion.
Innovation Solution
Administering a CLEC-1 antagonist to block the inhibitory effects of CLEC-1, thereby enhancing T cell proliferation and activation, particularly by increasing Th1 and Th17 responses, which are crucial for anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CLEC-1 is active, then myeloid cell activation is inhibited and immune evasion is promoted, but T cell response and anti-tumor immunity are suppressed
Solution Approach 1:
The patent applies preliminary anti-action by administering a CLEC-1 antagonist before or during tumor development to prevent CLEC-1-mediated immune suppression. The antagonist blocks CLEC-1 activity in advance, preventing the harmful inhibitory effects on myeloid cell activation and T cell response, thereby maintaining reliable anti-tumor immunity throughout the disease process.
Solution Approach 2:
The patent converts the harmful immune suppression caused by CLEC-1 into a benefit by using the CLEC-1 antagonist to block its inhibitory pathway. By preventing CLEC-1 from suppressing myeloid cells and T cells, the treatment transforms the immune evasion mechanism into an enhanced anti-tumor immune response, where blocked CLEC-1 signaling now promotes rather than inhibits immunity.
2Productivity
If CLEC-1 antagonist is administered, then T cell activation is enhanced, but the complexity of treatment increases
Solution Approach 1:
The patent uses a CLEC-1 antagonist as an intermediary molecule to mediate between the immune system and the inhibitory CLEC-1 pathway. This single intermediary compound simplifies the treatment approach by targeting one key checkpoint (CLEC-1) to achieve broad enhancement of T cell activation and anti-tumor immunity, rather than requiring complex combination therapies.
Data Source
AI summary
The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.